Nerve growth factor signaling in prostate health and disease

References

• Abdiche YN, Malashock DS, Pons J. 2008. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 17:1326–1335.
   PubMed Web of Science ®Google Scholar
• Aloe L, Cossari C, Callissano P, Levi-Montalcini R. 1981. Somatic and behavioral postnatal effects of fetal injections of nerve growth factor antibodies in the rat. Nature. 291:413–415.
   PubMed Web of Science ®Google Scholar
• Ayer-LeLievre C, Olson L, Ebendal T, Hallböök F, Persson H. 1988. Nerve growth factor mRNA and protein in the testis and epididymis of mouse and rat. Proc Natl Acad Sci USA. 85:2628–2632.
   PubMedGoogle Scholar
• Banerjee S, Li Y, Wang Z, Sarkar FH. 2008. Multi-targeted therapy of cancer by genistein. Cancer Lett. 269:226–242.
   PubMed Web of Science ®Google Scholar
• Barker PA. 2004. P75 is positively promiscuous: Novel partners and new insights. Neuron. 42:529–533.
   PubMed Web of Science ®Google Scholar
• Barker PA. 2007. High affinity not in the vicinity?. Neuron. 53:1–4.
   PubMed Web of Science ®Google Scholar
• Bibel M, Barde YA. 2000. Neurotrophin: Key regulators of cell fate and cell shape in the vertebral nervous system. Genes Dev. 14:2919–2937.
   PubMed Web of Science ®Google Scholar
• Bibel M, Hoppe H, Barde YA. 1999. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J. 18:616–622.
   PubMed Web of Science ®Google Scholar
• Bilderback TR, Gazula VR, Dobrowsky R. 2001. Phosphoinositide 3-kinase regulates crosstalk between TrkA tyrosine kinase and p75(NTR)-dependent sphingolipid signaling pathways. J Neurochem. 76:1540–1551.
   PubMed Web of Science ®Google Scholar
• Blochl A, Blochl R. 2007. A cell-biological model of p75NGFR signaling. J Neurochem. 102:289–305.
   PubMed Web of Science ®Google Scholar
• Bradshaw RA, Murray-Rust J, Ibanez CF, McDonald NQ, Lapatto R, Blundell TL. 1994. Nerve growth factor: Structure/function relationships. Protein Sci. 3:1901–1913.
   PubMed Web of Science ®Google Scholar
• Bredesen DE, Rabizadeh S. 1997. p75NTR ad apoptosis: Trk-dependent and Trk-independent effects. Trends Neurosci. 20:287–290.
   PubMed Web of Science ®Google Scholar
• Casademunt E, Carter BD, Benzel I, Frade JM, Dechant G, Barde YA. 1999. The zinc finger protein NRIF interacts with the neurotrophin receptor p75(NTR) and participates in programmed cell death. EMBO J. 18:6050–6061.
   PubMed Web of Science ®Google Scholar
• Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Sachenz L, Contreras H, Huidobro C. 2006. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 24:261–268.
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 94:1099–1106.
   PubMed Web of Science ®Google Scholar
• Chao MV. 2003. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci. 4:299–309.
   PubMed Web of Science ®Google Scholar
• Chao M, Bothwell M. 2002. Neurotrophins: To cleave or not to cleave. Neuron. 33:9–12.
   PubMed Web of Science ®Google Scholar
• Clementi M, Sanchez C, Benitez DA, Contreras HR, Huidobro C, Cabezas J, Acevedo C, Castello EA. 2009. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 69:1025–1033.
   PubMed Web of Science ®Google Scholar
• Clinical Trials [Internet]. Identifier: NCT00545129: A Study of Tanezumab as Add-On Therapy to Opioid Medication in Patients with Pain Due to Cancer that has Spread to Bone. Lister Hill National Center for Biomedical Communications, US National Library of Medicine, US National Institutes of Health. Available from www.clinicaltrials.gov..
   Google Scholar
• Delsite R, Djakiwe D. 1996. Anti-proliferative effect of the kinases inhibitors K252a on human prostatic carcinoma cell line. J Androl. 17:481–490.
   PubMed Web of Science ®Google Scholar
• Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT. 1998. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res. 4:1887–1898.
   PubMed Web of Science ®Google Scholar
• Djakiew D. 1992. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl. 13:476–487.
   PubMedGoogle Scholar
• Djakiew D. 2000. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 42:150–160.
   PubMed Web of Science ®Google Scholar
• Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M. 1991. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. 51:3304–3310.
   PubMed Web of Science ®Google Scholar
• Djakiew D, Pflug B, Onoda M. 1993. Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. Adv Exp Med Biol. 330:185–202.
   PubMedGoogle Scholar
• Djakiew D, Delsite R, Dalal R, Pflug B. 1996. The role of the low affinity nerve growth factor receptor and the high affinity Trk receptor in human prostate carcinogenesis. Radiat Oncol Investig. 3:333–339.
   Google Scholar
• Dollé L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H. 2004. Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets. 4:463–470.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV. 2007. Drug Insight: Clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 3:157–167.
   PubMedGoogle Scholar
• Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M. 2007. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol. 30:193–200.
   PubMed Web of Science ®Google Scholar
• Fiorentini C, Facchetti M, Finardi A, Sigala S, Páez-Pereda M, Sher E, Spano P, Missale C. 2002. Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. Eur J Endocrinol. 147:371–379.
   PubMed Web of Science ®Google Scholar
• Freund-Michel V, Frossard N. 2008. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther. 117:52–76.
   PubMed Web of Science ®Google Scholar
• Geetha T, Jiang J, Wooten MW. 2005. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol Cell. 20:301–312.
   PubMed Web of Science ®Google Scholar
• Geldof AA, van Haarst EP, Newling DWW. 1998. Neurotrophic factors in prostate and prostatic cancer. Prostate Cancer Prostatic Dis. 1:236–241.
   PubMed Web of Science ®Google Scholar
• Graham CW, Lynch JH, Djakiew D. 1992. Distribution of nerve growth factor-like protein and nerve growth factor receptors in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol. 147:1444–1447.
   PubMed Web of Science ®Google Scholar
• He XL, Garcia KC. 2004. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science. 304:870–875.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F. 2008. European Association of Urology 2008. EAU guidelines on prostate cancer. Eur Urol. 53:68–80.
   PubMed Web of Science ®Google Scholar
• Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu MT, Mirand EA, Munphy GP. 1983. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809–1818.
   PubMed Web of Science ®Google Scholar
• Howe CL, Mobley WC. 2005. Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol. 15:40–48.
   PubMed Web of Science ®Google Scholar
• Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG, Barthold CM, Peters CM, Buus RJ, Ghilardi JR, Lewis JL, Kuskowski MA, Mantyh PW. 2007. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain. 133:183–196.
   PubMed Web of Science ®Google Scholar
• Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. 1986. Expression and structure of the human NGF receptor. Cell. 47:545–554.
   PubMed Web of Science ®Google Scholar
• Khwaja F, Tabassum A, Allen J, Djakiew D. 2006. The p75NTR tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem Biophys Rews Commun. 341:1184–1192.
   PubMed Web of Science ®Google Scholar
• Khwaja F, Quann EJ, Pattabiraman N, Wynne S, Djakiew D. 2008. Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther. 7:3539–3545.
   PubMed Web of Science ®Google Scholar
• Khwaja F, Wynne S, Posey I, Djakiew D. 2009. 3,3′-Diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res. 2:566–571.
   PubMed Web of Science ®Google Scholar
• Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW. 2007. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res. 22:1732–1742.
   PubMed Web of Science ®Google Scholar
• Krüttgen A, Schneider I, Weis J. 2006. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol. 16:304–310.
   PubMed Web of Science ®Google Scholar
• Krygier S, Djakiew D. 2001. Molecular characterization of the loss of p75(NTR) expression in human prostate tumor cells. Mol Carcinog. 31:46–55.
   PubMed Web of Science ®Google Scholar
• Krygier S, Djakiew D. 2002. Neurotrophin receptor p75NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer. 98:1–7.
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science. 237:1154–1162.
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. 1996. Nerve growth factor: From neurotrophin to neurokine. Trends Neurosci. 19:514–520.
   PubMed Web of Science ®Google Scholar
• Li C, Watanabe G, Weng Q, Jin W, Furuta C, Suzuki AK, Kawaguchi M, Taya K. 2005. Expression of nerve growth factor (NGF), and its receptors TrkA and p75 in the reproductive organs of the adult male rats. Zoolog Sci. 22:933–937.
   PubMed Web of Science ®Google Scholar
• Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW. 2002. Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience. 113:155–166.
   PubMed Web of Science ®Google Scholar
• Makkerh JP, Ceni C, Auld DS, Vaillancourt F, Dorval G, Barker PA. 2005. p75 neurotrophin receptor reduces ligand-induced Trk receptor ubiquitination and delays Trk receptor internalization and degradation. EMBO Rep. 6:936–941.
   PubMed Web of Science ®Google Scholar
• Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P. 1999. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology. 140:329–334.
   PubMed Web of Science ®Google Scholar
• Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. 1989. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol. 9:24–33.
   PubMed Web of Science ®Google Scholar
• Martínez-Serrano A, Olsson M, Gates MA, Björklund A. 1998. In utero gene transfer reveals survival effects of nerve growth factor on rat brain cholinergic neurones during development. Eur J Neurosci. 10:263–271.
   PubMed Web of Science ®Google Scholar
• McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell TL. 1991. New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature. 354:411–414.
   PubMed Web of Science ®Google Scholar
• McGrogan D, Saint-Andrè JP, Dicou E. 1992. Expression of nerve growth factor receptor gene in human tissue and in prostatic adenocarcinoma cell line. J Neurochem. 59:1381–1391.
   PubMed Web of Science ®Google Scholar
• McMahon SB, Bennett DL, Priestley JV, Shelton DL. 1995. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med. 1:774–780.
   PubMed Web of Science ®Google Scholar
• Meakin SO, Shooter EM. 1992. The nerve growth factor family of receptors. Trends Neurosci. 15:323–331.
   PubMed Web of Science ®Google Scholar
• Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, Balsari A, Spano P. 1993. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA. 90:7961–7965.
   PubMed Web of Science ®Google Scholar
• Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E, Spano PF. 1998. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci USA. 95:5366–5371.
   PubMed Web of Science ®Google Scholar
• Montano X, Djamgoz MB. 2004. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett. 571:1–8.
   PubMed Web of Science ®Google Scholar
• Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P. 1996. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab. 81:3930–3937.
   PubMed Web of Science ®Google Scholar
• Moul JW. 2003. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer. 2:87–97.
   PubMedGoogle Scholar
• Mouravier V, Mayes JM, Polascik TJ. 2009. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol. 6:205–215.
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Djakiew D. 2006. The p75NTR metastasis suppressor inhibits urokinases plasminogen activator, matrix metalloprotease 2 and matrix metalloprotease 9 in PC3 prostate cancer cell. Clin Exp Metastasis. 23:107–116.
   PubMed Web of Science ®Google Scholar
• Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu S-M, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 3:2493–2500.
   PubMed Web of Science ®Google Scholar
• Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D. 2008. Nerve growth factor as an angiogenic factor. Microvasc Res. 75:135–141.
   PubMed Web of Science ®Google Scholar
• Ohnuki Y, Marnell MM, Bobcock MS, Lechner JF, Kaighn E. 1980. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res. 40:524–534.
   PubMed Web of Science ®Google Scholar
• Papatsoris AG, Lioltsia D, Deliveliotis C. 2007. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs. 16:303–309.
   PubMed Web of Science ®Google Scholar
• Paul AB, Grant ES, Habib FK. 1996. The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: Relationship to neuroendocrine differentiation. Br J Cancer. 74:1990–1996.
   PubMed Web of Science ®Google Scholar
• Perez M, Regan T, Pflug B, Lynch J, Djakiew D. 1997. Loss of the low affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate. 30:274–279.
   PubMed Web of Science ®Google Scholar
• Pflug B, Djakiew D. 1998. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced by activation of programmed cell death. Mol Carcinog. 23:107–114.
   Web of Science ®Google Scholar
• Pflug BR, Onoda M, Lynch JH, Djakiew D. 1992. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res. 52:5403–5406.
   PubMed Web of Science ®Google Scholar
• Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D. 1995. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology. 136:262–268.
   PubMed Web of Science ®Google Scholar
• Pomerantz M, Kantoff P. 2007. Advances in the treatment of Prostate cancer. Ann Rev Med. 58:472–479.
   Web of Science ®Google Scholar
• Páez Pereda M, Missale C, Grübler Y, Arzt E, Schaaf L, Stalla GK. 2000. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol. 167:99–106.
   PubMed Web of Science ®Google Scholar
• Quann EJ, Khwaja F, Djakiew D. The p38 MAPK pathway mediates aryl propionic acid induced messenger RNA stability of p75 NTR in prostate cancer cells. Cancer Res. 2007a; 67:11402–11410.
   PubMed Web of Science ®Google Scholar
• Quann EJ, Khwaja F, Zavitz KH, Djakiew D. The aryl propionic acid R-flurbiprofen selectively induces p75-dependent decreased survival of prostate tumor cells. Cancer Res. 2007b; 67:3254–3262.
   PubMed Web of Science ®Google Scholar
• Rahbek UL, Dissing S, Thomassen C, Hansen AJ, Tritsaris K. 2005. Nerve growth factor activates aorta endothelial cells causing PI3K/Akt-and ERK-dependent migration. Pflugers Arch Eur J Physiol. 450:355–361.
   PubMed Web of Science ®Google Scholar
• Renehan AG, O'Dwyer ST, Shalet SM. 2004. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systemic review and metaregression analysis. Lancet. 363:1346–1353.
   PubMed Web of Science ®Google Scholar
• Riccio A, Pierchala BA, Ciarallo CL, Ginty DD. 1997. An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons. Science. 277:1097–1100.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Clementi M, Benitez D, Contreras H, Huidobro C, Castellon E. 2005. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cultures for human prostate adenocarcinoma. Prostate. 65:195–202.
   PubMed Web of Science ®Google Scholar
• Sarker D, Reid AH, Yap TA, de Bono JS. 2009. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 15:4799–4805.
   PubMed Web of Science ®Google Scholar
• Segal RA, Greenberg ME. 1996. Intracellular signaling pathways activated by neurotrophic factor. Annu Rev Neurosci. 19:463–489.
   PubMed Web of Science ®Google Scholar
• Seidl K, Holstein AF. 1990. Evidence for the presence of nerve growth factor (NGF) and NGF receptors in human testis. Cell Tissue Res. 261:549–554.
   PubMed Web of Science ®Google Scholar
• Shonukan O, Bagayogo I, McCrea P, Chao M, Hempstead B. 2003. Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene. 22:3616–3623.
   PubMed Web of Science ®Google Scholar
• Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P. 1999. Suppression of telomerase, reexpression of KAI 1 and abrogation of tumorigenity by nerve growth factor in rpostae cancer cell lines. Clin Cancer Res. 5:1211–1218.
   PubMed Web of Science ®Google Scholar
• Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E, Spano P. 2002. Nerve growth factor induces the reexpression of functinal androgen receptor and p75NGFR in the androgen-insensitive prostate cancer cell line DU 145. Eur J Endocrinol. 147:407–415.
   PubMed Web of Science ®Google Scholar
• Sigala S, Bodei S, Missale C, Zani D, Simeone C, Cunico SC, Spano PF. 2008. Gene expression profile of prostate cancer cell line: Effect of nerve growth factor treatment. Mol Cell Endocrinol. 284:11–20.
   PubMed Web of Science ®Google Scholar
• Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ. 2006. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology. 147:2112–2121.
   PubMed Web of Science ®Google Scholar
• Sortino MA, Condorelli F, Vancheri C, Vancheri C, Chiarenza A, Bernardini R, Consoli U, Canonico PL. 2000. Mitogenic effects of NGF in LCNaP prostate adenocarcinoma cells: Role of the high and low affinity NGF receptors. Mol Endocrinol. 14:124–136.
   PubMedGoogle Scholar
• Stone HR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. 1978. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer. 21:274–281.
   PubMed Web of Science ®Google Scholar
• Tacconelli A, Farina AR, Caprabianca L, de Sanctis G, Tessitore G, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, Giulino A, Mackay AR. 2004. TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 6:347–360.
   PubMed Web of Science ®Google Scholar
• Vinores SA, Perez-Polo JR. 1983. Nerve growth factor and neural oncology. Neurosci Res. 9:81–100.
   Web of Science ®Google Scholar
• Watson JJ, Allen SJ, Dawbarn D. 2008. Targeting nerve growth factor in pain: What is the therapeutic potential?. BioDrugs. 22:349–359.
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. 2000. Rational basis for Trk inhibition therapy for prostate cancer. Prostate. 45:140–148.
   PubMed Web of Science ®Google Scholar
• Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. 2007. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 53:25–38.
   PubMedGoogle Scholar
• Weier HU, Rhein AP, Shadravan F, Collins C, Polikoff D. 1995. Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. Genomics. 26:390–393.
   PubMed Web of Science ®Google Scholar
• Yeiser EC, Rutkoski NJ, Naito A, Inoue J, Carter BD. 2004. Neurotrophin signalling through the p75 receptor is deficient in traf6-/- mice. J Neurosci. 24:10521–10529.
   PubMed Web of Science ®Google Scholar
• Zampieri N, Chao M. 2004. The p75 NGF receptor exposed. Science. 304:833–834.
   PubMed Web of Science ®Google Scholar
• Zhou J, Scholes J, Hsieh JT. 2001. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev. 20:351–362.
   PubMed Web of Science ®Google Scholar